{"filings":[{"id":499048,"accession_number":"0001213900-26-058427","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-05-18T20:05:31+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Quantum Cyber licenses drone/cyber IP from BP United for $5M cash and 20M shares","event_type":"other_material","confidence":"high","bullets":["Exclusive, perpetual, worldwide license to BP United's IP (patents, trademarks, know-how) for drones and cyber applications.","Consideration: $5M cash plus 20M restricted shares (6-month lock-up, 5% volume restriction) at prior closing price.","Conditions precedent: satisfactory IP due diligence, USPTO corrective filings, and execution of securities purchase agreement; Company may terminate if unmet within 90 days.","Entered Advisory Agreement with Alexander Gurevich: 5M restricted shares at $0.40 for strategic advisory (12-month term).","Appointed Peter O'Rourke as director effective May 13, 2026; he has government/defense background."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96472,"accession_number":"0001213900-26-053865","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Quantum Cyber increases equity distribution capacity to $100M; CFO Caragol moves to consulting role","event_type":"other_material","confidence":"high","bullets":["Equity distribution agreement amended; offering amount increased from $10M to $100M.","CFO William Caragol enters consulting agreement, effective April 22, 2026, with $20,000 monthly retainer.","Caragol commits up to 50% of professional time; term through August 31, 2026, with possible monthly extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96471,"accession_number":"0001213900-26-048635","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","5.03","5.07","9.01"],"status":"ready","headline":"Quantum Cyber N.V. issues $6M preferred shares; David Lazar gains >95% voting control and Co-CEO resigns","event_type":"other_material","confidence":"high","bullets":["Second closing on Apr 22, 2026: issued Series D/E preferred convertible into up to 225M ordinary shares each, representing >90% fully diluted shares.","David Lazar becomes controlling shareholder with >95% voting rights; four directors and Co-CEO Guido Baechler resigned; David Natan and Avraham Ben-Tzvi appointed.","Name changed from Mainz Biomed N.V. to Quantum Cyber N.V.; authorized ordinary shares increased from 45M to 900M, preferred from 5M to 100M.","All 11 proposals approved at Apr 22 Extraordinary General Meeting, including ratification of board appointments and share issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96470,"accession_number":"0001213900-26-044125","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Mainz Biomed sells next-gen CRC screening IP for $1.25M, updates Nasdaq equity compliance","event_type":"other_material","confidence":"high","bullets":["Entered asset purchase agreement to sell Next Gen IP for $1.25M; closing by April 23, 2026.","Proceeds to be used for settlement of outstanding liabilities and general corporate purposes.","Continues development of pancreatic cancer detection product and explores post-quantum cybersecurity.","Believes stockholders' equity exceeds $2.5M after receiving $6M total from preferred share sale (Feb & March 2026).","Previously wound down ColoAlert product and next-gen colorectal cancer screening development in Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110395,"accession_number":"0001213900-26-034103","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mainz Biomed receives Nasdaq minimum bid price deficiency notice; 180-day cure period until Sep 16, 2026","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Mainz Biomed on Mar 20, 2026 that its share price closed below $1.00 for 30 consecutive business days through Mar 19, 2026.","Company has 180 calendar days, until Sep 16, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.","If not cured by Sep 16, 2026, Mainz may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to cure via reverse stock split.","There can be no assurance of regaining compliance or avoiding delisting; the letter has no immediate impact on trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110394,"accession_number":"0001213900-26-028672","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Quantum Cyber pre-funded $3M by David Lazar; targets acquisitions in quantum & cyber defense","event_type":"other_material","confidence":"high","bullets":["David Lazar pre-funded $3M second tranche; total investment now $6M.","Closing of tranche subject to stockholder approval and customary conditions.","Company aligns strategy with Trump Administration's National Cybersecurity Strategy released March 10, 2026.","Evaluating acquisition pipeline in quantum computing, post-quantum cryptography, zero-trust architecture.","No definitive acquisition agreements reached; management optimistic about pipeline quality."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110393,"accession_number":"0001213900-26-025940","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Mainz Biomed appoints cyber security veteran Robert Liscouski as Chairman; ticker changes to QUCY","event_type":"other_material","confidence":"high","bullets":["Robert P. Liscouski appointed Chairman effective March 11, 2026; election to be ratified at April 2026 EGM.","Nasdaq ticker symbol changes from MYNZ to QUCY effective March 12, 2026; company plans name change to Quantum Cyber.","Liscouski is former DHS Assistant Secretary for Infrastructure Protection and co-founder/CEO of Quantum Computing Inc. (QUBT).","Company winding down German subsidiary, focusing on U.S. pancreatic cancer screening, evaluating sale of colorectal cancer assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110392,"accession_number":"0001213900-26-016890","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","5.02","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Mainz Biomed secures $6M private placement, names David Lazar Chairman; pivots to pancreatic cancer","event_type":"other_material","confidence":"high","bullets":["First tranche of $3M closed Feb 13; second $3M expected after shareholder approval by April 15, 2026.","Preferred shares convertible into up to 95%+ of fully diluted shares; Lazar appointed Chairman and gets board nomination rights.","Company to focus on U.S. pancreatic cancer detection, evaluate sale of colorectal assets, wind down German sub.","Settlement agreements with officers/directors require ~$1.9M aggregate payments upon final closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110391,"accession_number":"0001213900-26-014378","cik":1874252,"company_name":"Quantum Cyber N.V.","ticker":"QUCY","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mainz Biomed raises $2.15M via ATM equity offering; fully utilizes prospectus supplement","event_type":"other_material","confidence":"high","bullets":["Sold 1,735,194 ordinary shares at prevailing market prices for gross proceeds of $2,152,822.40.","Prospectus supplement filed Dec 29, 2025, now fully utilized.","Overall ATM capacity of up to $10M remains available for future sales.","Sales agent Maxim Group LLC; net proceeds after commissions not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}